Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 162

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 162
---
 unwilling to adopt our products in light of the additional associated cost. Further,
any decline in the amount payors are willing to reimburse our customers for the procedures using our products may make it difficult for
customers to adopt our products and could create additional pricing pressure for us. We may be unable to sell our products on a profitable
basis if third-party payors deny coverage or reduce their current levels of reimbursement. The ability of our customers to obtain appropriate
coverage and reimbursement for our products or procedures using our products from government and private third-party payors is important
to our success.

Reimbursement
varies from state to state and plan to plan, and can significantly influence the acceptance of new products and services. Certain private
third-party payors may view some procedures using our products as experimental and may not provide coverage. Third-party payors may not
cover and reimburse the procedures using our products in whole or in part in the future, or payment rates may not be adequate, or both.
For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult
because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment
or procedure in which the product is used may not be available, which may impact physician utilization. Further, the adequacy of coverage
and reimbursement by third-party payors is also related to billing codes to describe procedures performed using our products. Hospitals
and physicians use several billing codes to bill for such procedures. Third-party payors may not continue to recognize the billing codes
available for use by our customers.

| 70 |

Healthcare reform
measures that may be adopted in the future may result in reductions in Medicare and other healthcare funding, more rigorous coverage criteria,
new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement
physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively
impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from
Medicare or other government programs may result in a similar reduction in payments from private payors.

After we develop
new products or seek to market our products for new indications, once approved or certified, we may find limited demand for the product
unless government and private third-party payors provide adequate coverage and reimbursement. Even with reimbursement approval and coverage
by government and private payors, providers submitting reimbursement claims may face delays